Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue
| Autor: | Pallawi Torka, Suchitra Sundaram, Dominick Lamonica, Kristopher Attwood, Francisco J. Hernandez-Ilizaliturri, Mazen Jizzini, Matthew Gravina |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
medicine.medical_specialty Biopsy Lymphoma T-Cell Article 03 medical and health sciences 0302 clinical medicine Bone marrow aspirate Bone Marrow Fluorodeoxyglucose F18 Positron Emission Tomography Computed Tomography Medicine T-cell lymphoma Humans In patient Neoplasm Staging Retrospective Studies medicine.diagnostic_test business.industry Hematology medicine.disease Lymphoma medicine.anatomical_structure Oncology Positron emission tomography 030220 oncology & carcinogenesis Positron-Emission Tomography Radiology Bone marrow business 030215 immunology |
| Zdroj: | Leuk Lymphoma |
| ISSN: | 1029-2403 |
| Popis: | The role of 18F-Fluoro-2-deoxy-D-glucose positron emission tomography combined with computerized tomography (PET-CT) in evaluation of bone marrow involvement (BMI) in patients with T-cell lymphoma (TCL) is poorly understood. We investigated whether PET-CT could replace bone marrow aspiration and biopsy (BMAB) in TCL. Sixty patients with newly diagnosed TCL who underwent both diagnostic PET-CT and BMAB were identified. BMI was tissue-confirmed in 15 (25%) cases, however only 8 of these 15 showed BMI on PET-CT (sensitivity of 53.3%, specificity of 100%). BMI by BMAB was associated with lower progression-free survival (PFS) (P=0.038) and overall survival (OS) (P=0.003) while PET-CT BMI was associated only with OS (P=0.02). BMI detected by BMAB in the setting of a negative PET-CT had similar inferior prognosis as BMI identified on PET-CT. Thus, PET-CT in TCL misses BMI in almost half of the cases detected by BMAB and hence cannot substitute BMAB in evaluation of TCL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|